The U.S. Food and Drug Administration expanded the approved indication for GSK’s RSV vaccine, granting broader clearance for use in additional adult populations. The decision follows post‑launch regulatory engagement and data submissions intended to refine target populations for prevention of respiratory syncytial virus. The expanded approval could help reverse flattening uptake after the vaccine’s initial rollout and affects commercial planning, dosing guidance and public health messaging for older adults at elevated risk of severe RSV disease.